Therefore, to avoid cardiac arrhythmia via down-regulation of the fraction of CD4+CD28null cells, a safe and feasible pre-optative stain-therapy could represent a potential therapeutic agent. This evidence concerns the gene CD4 and cardiac arrhythmia.